细菌性阴道病生物膜:治疗创新的靶点
- 作者: Rossolovskaya K.A.1, Trifonova N.S.1, Gadaeva I.V.1, Spivak L.G.1
-
隶属关系:
- I.M. Sechenov First Moscow State Medical University
- 期: 卷 11, 编号 4 (2024)
- 页面: 406-415
- 栏目: Reviews
- URL: https://journal-vniispk.ru/2313-8726/article/view/286420
- DOI: https://doi.org/10.17816/aog633897
- ID: 286420
如何引用文章
详细
细菌性阴道病(Bacterial Vaginosis, BV)是全球范围内最常见的阴道微生物群失调类型之一,同时是产科和妇科实践中各种并发症的重要风险因素。
尽管这一综合征已被研究多年,并且现有的临床实验室和仪器诊断方法不断完善,但BV的病因和发病机制仍未完全阐明。这可以从其高慢性化和高复发率的特点中看出。目前的标准治疗方法主要旨在根除病原体,但由于复发率高,治疗效果仍然有限,这需要进一步深入研究。研究表明,G. vaginalis 在尿生殖道黏膜上形成多菌种生物膜。
生物膜是微生物的集合体,其附着在上皮表面,并通过聚合物基质相互连接。生物膜改变了其内部微生物的特性,为其提供相互作用的条件。这不仅增强了与BV相关的细菌既有的致病特性,还赋予了它们新的特性,包括降低对以往有效抗菌药物和不利环境的敏感性,从而导致复发。
在大多数情况下,BV的治疗直接针对微生物,但对于被诊断为生物膜型BV的患者,这种治疗策略效果有限,往往导致复发。因此,目前的研究重点是明确复发性BV的原因,并开发针对生物膜基质破坏的抗生物膜药物。这些药物能够释放基质内的细菌,从而显著提高治疗效果。
作者简介
Kseniya A. Rossolovskaya
I.M. Sechenov First Moscow State Medical University
编辑信件的主要联系方式.
Email: dr.rossolovskaya@yandex.ru
ORCID iD: 0000-0002-7026-1607
SPIN 代码: 4432-5748
Graduate Student
俄罗斯联邦, MoscowNatalia S. Trifonova
I.M. Sechenov First Moscow State Medical University
Email: trifonova.nataly@mail.ru
ORCID iD: 0000-0002-2891-3421
SPIN 代码: 4753-5430
MD, Dr. Sci. (Medicine), Professor
俄罗斯联邦, MoscowIrina V. Gadaeva
I.M. Sechenov First Moscow State Medical University
Email: irina090765@gmail.com
ORCID iD: 0000-0003-0144-4984
SPIN 代码: 9593-1990
MD, Cand. Sci. (Medicine)
俄罗斯联邦, MoscowLeonid G. Spivak
I.M. Sechenov First Moscow State Medical University
Email: leonid.spivak@gmail.com
ORCID iD: 0000-0003-1575-6268
SPIN 代码: 5230-8811
MD, Dr. Sci. (Medicine), Professor
俄罗斯联邦, Moscow参考
- Letyaeva OI. Bacterial vaginosis: current opportunities and prospects for long-term control. Russian Bulletin of Obstetrician-Gynecologist. 2019;19(2):100–104. EDN: FHTCEF doi: 10.17116/rosakush201919021100
- Tabatabaei N, Eren AM, Barreiro LB, et al. Vaginal microbiome in early pregnancy and subsequent risk of spontaneous preterm birth: a case-control study. BJOG. 2019;126(3):349–358. doi: 10.1111/1471-0528.15299
- Johnston W, Ware A, Kuiters WF, et al. In vitro bacterial vaginosis biofilm community manipulation using endolysin therapy. Biofilm. 2022;5:100101. doi: 10.1016/j.bioflm.2022.100101
- Bretelle F, Loubière S, Desbriere R, et al. Effectiveness and costs of molecular screening and treatment for bacterial vaginosis to prevent preterm birth: The AuTop randomized clinical trial. JAMA Pediatr. 2023;177(9):894–902. doi: 10.1001/jamapediatrics.2023.2250
- Novikova SV, Tsivtsivadze EB, Fedotova AV. Bacterial vaginosis as a typical biofilm infection. Russian Bulletin of Obstetrician-Gynecologist. 2018;18(4):97–100. EDN: XWAUCT doi: 10.17116/rosakush201818497
- Kenyon C, Colebunders R, Crucitti T. The global epidemiology of bacterial vaginosis: a systematic review. Am J Obstet Gynecol. 2013;209(6):505–523. doi: 10.1016/j.ajog.2013.05.006
- Peebles K, Velloza J, Balkus JE, et al. High global burden and costs of bacterial vaginosis: a systematic review and meta-analysis. Sex Transm Dis. 2019;46(5):304–311. doi: 10.1097/OLQ.0000000000000972
- Dobrokhotova YuE, Kazantseva VD, Bondarenko KR. Bacterial vaginosis: modern anti-relapse treatment tactics. RMJ. 2022;(8):61–65. EDN: GVQLAZ
- Javed A, Parvaiz F, Manzoor S. Bacterial vaginosis: An insight into the prevalence, alternative treatments regimen and its associated resistance patterns. Microb Pathog. 2019;127:21–30. doi: 10.1016/j.micpath.2018.11.046
- Reiter S, Kellogg Spadt S. Bacterial vaginosis: a primer for clinicians. Postgrad Med. 2019;131(1):8–18. doi: 10.1080/00325481.2019.1546534
- Muzny CA, Cerca N, Elnaggar JH, et al. State of the Art for Diagnosis of Bacterial Vaginosis. J Clin Microbiol. 2023;61(8):e0083722. doi: 10.1128/jcm.00837-22
- Bacterial vaginosis: Clinical recommendations under. Moscow, 2022 [cited 2024 Jun 02]. Available from: https://cr.minzdrav.gov.ru/recomend/206_2 (In Russ.)
- Chen C, Song X, Wei W, et al. The microbiota continuum along the female reproductive tract and its relation to uterine-related diseases. Nat Commun. 2017;8(1):875. doi: 10.1038/s41467-017-00901-0
- Pekmezovic M, Mogavero S, Naglik JR, Hube B. Host-pathogen interactions during female genital tract infections. Trends Microbiol. 2019;27(12):982–996. doi: 10.1016/j.tim.2019.07.006
- Döderlein A. Das scheidensekret und seine bedeutung für das puerperalfieber. Leipzig: Verlag von Eduard Besold; 1892.
- Leopold S. Heretofore undescribed organism isolated from the genitourinary system. US Armed Forces Med. 1953;4(2):263–266.
- Gardner HL, Dukes CD. Haemophilus vaginalis vaginitis: a newly defined specific infection previously classified non-specific vaginitis. Am J Obstet Gynecol. 1955;69(5):962–976.
- Zinnemann K, Turnerg C. The taxonomic position of ‘Haemophilus vaginalis’ (Corynebacterium vaginale). J Pathol Bacteriol. 1963;85(1):213–219. doi: 10.1002/PATH.1700850120
- Greenwood JR, Pickett MJ. Transfer of Haemophilus vaginalis Gardner and Dukes to a new genus, Gardnerella: G. vaginalis (Gardner and Dukes). Int J Syst Bacteriol. 1980;30(1):170–178. doi: 10.1099/00207713-30-1-170
- Piot P, van Dyck E, Goodfellow M, Falkow S. A taxonomic study of Gardnerella vaginalis (Haemophilus vaginalis) Gardner and Dukes 1955. J Gen Microbiol. 1980;119(2):373–396. doi: 10.1099/00221287-119-2-373
- Piot P. Gardnerella, streptobacillus, spirillum, and calymmatobacterium. In: Balows A, Hausler WJ Jr, Herrmann KL, Isenberg HD, Shadomy HJ, editors. Manual of Clinical Microbiology. 5th ed. Washington, D.C: American Society for Microbiology; 1991:483–487.
- Sadhu K, Domingue PA, Chow AW, et al. Gardnerella vaginalis has a Gram-positive cell-wall ultrastructure and lacks classical cell-wall lipopolysaccharide. J. Med. Microbiol. 1989;29(3):229–235. doi: 10.1099/00222615-29-3-229
- Scott TG, Curran B, Smyth CJ. Electron microscopy of adhesive interactions between Gardnerella vaginalis and vaginal epithelial cells, McCoy cells and human red blood cells. J Gen Microbiol. 1989;135(3):475–480. doi: 10.1099/00221287-135-3-475
- Taylor-Robinson D. The bacteriology of Gardnerella vaginalis. Scand J Urol. Nephrol Suppl. 1984;86:41–55.
- Ilyina TS, Romanova YuM. The role of bacterial biofilms in chronic infectious processes and the search for methods to combat them. Molecular Genetics, Microbiology and Virology. 2021;39(2):14–24. EDN: RHLJAM doi: 10.17116/molgen20213902114
- Khryanin AA. Microbial biofilms: modern concepts. Antibiotics and Chemotherapy. 2020;65(5–6):70–77. EDN: NQITOE doi: 10.37489/0235-2990-2020-65-5-6-70-77
- Jung HS, Ehlers MM, Lombaard H, et al. Etiology of bacterial vaginosis and polymicrobial biofilm formation. Crit Rev Microbiol. 2017;43(6):651–667. doi: 10.1080/1040841X.2017.1291579
- Pestrikova TYu, Yurasova EA, Kotelnikova AV, et al. Modern approach to treatment of a recurrent bacterial vaginosis at women of the reproductive period. Gynecology. 2018;20(2):55–58. EDN: XTGRVB doi: 10.26442/2079-5696_2018.2.55-58
- Nickel JC, Ruseska I, Wright JB, Costerton JW. Tobramycin resistance of cells of Pseudomonas aeruginosa growing as a biofilm on urinary catheter material. Antimicrob Agents Chemother. 1985;27(4):619–624. doi: 10.1128/AAC.27.4.619
- Berezovskaya ES, Makarov IO, Gomberg MA, et al. Biofilm formation at the bacterial vaginosis. Obstetrics, Gynecology and Reproduction. 2013;7(2):34–36. EDN: RRPOER
- Simões M, Simões LC, Vieira MJ. Species association increases biofilm resistance to chemical and mechanical treatments. Water Res. 2009;43(1):229–237. doi: 10.1016/j.watres.2008.10.010
- Khan J, Tarar SM, Gul I, et al. Challenges of antibiotic resistance biofilms and potential combating strategies: a review. 3 Biotech. 2021;11(4):169. doi: 10.1007/s13205-021-02707-w
- Michaelis C, Grohmann E. Horizontal gene transfer of antibiotic resistance genes in biofilms. Antibiotics (Basel). 2023;12(2):328. doi: 10.3390/antibiotics12020328
- Bonnardel F, Haslam SM, Dell A, et al. Proteome-wide prediction of bacterial carbohydrate-binding proteins as a tool for understanding commensal and pathogen colonisation of the vaginal microbiome. NPJ Biofilms Microbiomes. 2021;7(1):49. doi: 10.1038/s41522-021-00220-9
- Marín E, Haesaert A, Padilla L, et al. Unraveling Gardnerella vaginalis surface proteins using cell shaving proteomics. Front Microbiol. 2018;9:975. doi: 10.3389/fmicb.2018.00975
- Hardy L, Jespers V, Abdellati S, et al. A fruitful alliance: the synergy between Atopobium vaginae and Gardnerella vaginalis in bacterial vaginosis-associated biofilm. Sex Transm Infect. 2016;92(7):487–491. doi: 10.1136/sextrans-2015-052475
- Castro J, Machado D, Cerca N. Unveiling the role of Gardnerella vaginalis in polymicrobial Bacterial Vaginosis biofilms: the impact of other vaginal pathogens living as neighbors. ISME J. 2019;13(5):1306–1317. doi: 10.1038/s41396-018-0337-0
- Castro J, Cerca N. BV and non-BV associated Gardnerella vaginalis establish similar synergistic interactions with other BV-associated microorganisms in dual-species biofilms. Anaerobe. 2015;36:56–59. doi: 10.1016/j.anaerobe.2015.10.008
- Schwebke JR, Muzny CA, Josey WE. Role of Gardnerella vaginalis in the pathogenesis of bacterial vaginosis: a conceptual model. J Infect Dis. 2014;210(3):338–343. doi: 10.1093/infdis/jiu089
- Shvartsman E, Hill JE, Sandstrom P, MacDonald KS. Gardnerella revisited: species heterogeneity, virulence factors, mucosal immune responses, and contributions to bacterial vaginosis. Infect Immun. 2023;91(5):e0039022. doi: 10.1128/iai.00390-22
- Coudray MS, Madhivanan P. Bacterial vaginosis — A brief synopsis of the literature. Eur J Obstet Gynecol Reprod Biol. 2020;245:143–148. doi: 10.1016/j.ejogrb.2019.12.035
- Abaturov AE. Polysaccharide-degrading enzymes as agents dispersing bacterial biofilms. Zdorov’e Rebenka. 2020;15(4):271–278. EDN: WKPGMH doi: 10.22141/2224-0551.15.4.2020.208478
- Marshall AO. Managing recurrent bacterial vaginosis: insights for busy providers. Sex Med Rev. 2015;3(2):88–92. doi: 10.1002/smrj.45
补充文件
